Literature DB >> 3125250

Protein L. A novel bacterial cell wall protein with affinity for Ig L chains.

L Björck1.   

Abstract

A novel Ig-binding protein has been isolated from the surface of bacteria belonging to the anaerobic species Peptococcus magnus. To solubilize the protein, peptococci were treated with different proteolytic enzymes (papain, pepsin, and trypsin) or with mutanolysin, a bacteriolytic agent known to digest the cell walls of streptococci. Papain, trypsin, and mutanolysin all solubilized peptides showing affinity for radiolabeled human IgG in Western blot analysis. Compared with papain and trypsin, mutanolysin liberated a more homogeneous material, which also had a higher m.w. This mutanolysin-solubilized protein (Mr 95 kDa) was obtained highly purified by a single isolation step on IgG-Sepharose, and the molecule was found to exhibit unique Ig-binding properties. Thus, in dot blots and in Western blots, human IgG, F(ab')2 and Fab fragments of IgG, and human kappa and lambda L chains all showed affinity for the protein. Moreover, the molecule also bound human IgM and IgA, whereas no binding was recorded for IgG-Fc fragments or IgG H chains. Finally, the protein bound to human polyclonal Ig L chains immobilized on polyacrylamide beads. These different data demonstrate that the isolated peptococcal protein binds Ig through L chain interaction. The name protein L is therefore suggested for this novel Ig-binding bacterial cell wall protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125250

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  By-passing selection: direct screening for antibody-antigen interactions using protein arrays.

Authors:  L J Holt; K Büssow; G Walter; I M Tomlinson
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

Review 2.  Virulence factors in anaerobic bacteria.

Authors:  T Hofstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

3.  Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L.

Authors:  Muriel Viau; Nancy S Longo; Peter E Lipsky; Lars Björck; Moncef Zouali
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

4.  Expression of high-affinity human antibody fragments in bacteria.

Authors:  Romain Rouet; David Lowe; Kip Dudgeon; Brendan Roome; Peter Schofield; David Langley; John Andrews; Peter Whitfeld; Lutz Jermutus; Daniel Christ
Journal:  Nat Protoc       Date:  2012-02-02       Impact factor: 13.491

5.  Identification of a mycoplasmal protein which binds immunoglobulins nonimmunologically.

Authors:  A G Alexander; H R Lowes; G E Kenny
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 6.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

7.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

Review 8.  B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies.

Authors:  Carl S Goodyear; Gregg J Silverman
Journal:  Springer Semin Immunopathol       Date:  2005-03

9.  Purification of antibody fragments via interaction with detergent micellar aggregates.

Authors:  Gunasekaran Dhandapani; Ellen Wachtel; Ishita Das; Mordechai Sheves; Guy Patchornik
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

10.  Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E.

Authors:  A Genovese; J P Bouvet; G Florio; B Lamparter-Schummert; L Björck; G Marone
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.